@article{TP16973,
author = {Sasigarn A. Bowden and John D. Mahan},
title = {Zoledronic acid in pediatric metabolic bone disorders},
journal = {Translational Pediatrics},
volume = {6},
number = {4},
year = {2017},
keywords = {},
abstract = {Zoledronic acid (ZA), a highly potent intravenous bisphosphonate (BP), has been increasingly used in children with primary and secondary osteoporosis due to its convenience of shorter infusion time and less frequent dosing compared to pamidronate. Many studies have also demonstrated beneficial effects of ZA in other conditions such as hypercalcemia of malignancy, fibrous dysplasia (FD), chemotherapyrelated osteonecrosis (ON) and metastatic bone disease. This review summarizes pharmacologic properties, mechanism of action, dosing regimen, and therapeutic outcomes of ZA in a variety of metabolic bone disorders in children. Several potential novel uses of ZA are also discussed. Safety concerns and adverse effects are also highlighted.},
issn = {2224-4344}, url = {https://tp.amegroups.org/article/view/16973}
}